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An 89-year-old man presented with multiple cerebral infarction, and subsequently, thrombotic throm-
bocytopenic purpura (TTP) was diagnosed. He was treated with plasma exchange (PEX), however, despite
the initial response, he was refractory to PEX. The addition of rituximab led to a sustained complete
response. This case presents the oldest known reported TTP patient treated with rituximab and shows
that rituximab can be administered successfully to very elderly patients with refractory TTP, and that
therapeutic modalities similar to those for younger patients can be considered for this age group. This
case also shows that elderly TTP patients may present with uncommon symptoms.
Copyright © 2016, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Thrombotic thrombocytopenic purpura (TTP) is a rare life-
threatening disorder characterized by fever, microangiopathic he-
molytic anemia, thrombocytopenia, transient focal neurologic
symptoms, and renal impairment. TTP is mediated by hereditary or
acquired deﬁciency of a disintegrin-like and metalloprotease with
thorombospondin type 1 motif 13 (ADAMTS13) activity.1 Acquired
TTP is caused by a deﬁciency of ADAMTS13 due to autoantibodies
that inhibit ADAMTS13 activity.2 ADAMTS13 is a plasma metal-
loproteinase that cleaves von Willebrand factor (VWF), and deﬁ-
ciency of plasma ADAMTS13 activity leads to spontaneous VWF-
dependent platelet adhesion and aggregation, ultimately resulting
in disseminated microvascular thrombi formation.1,2
The prognosis of acquired TTP patients was poor and the mor-
tality rate was as high as 90% before the introduction of therapeutic
plasma exchange (PEX).3 PEX has greatly improved the prognosis of
TTP and the mortality rate has been greatly reduced to 20e30%.
PEX, usually with corticosteroids, is currently the ﬁrst-line treat-
ment of acquired TTP.3e5 However, 10e42% of patients are re-
fractory to or relapse after PEX and require additional therapies.3Hospital, 1e9 Akashi-cho,
inical Gerontology & Geriatrics. Pub
d/4.0/).The efﬁcacy of rituximab, a humanized monoclonal antibody
against CD20, for refractory or relapsed TTP patients after PEX has
been conﬁrmed, leading to remission in 87e100% of the patients,
through depletion of CD20-positive B lymphocytes that are
responsible for production of autoantibodies against ADAMTS13,
and currently rituximab is the ﬁrst treatment option for such
patients.3,6e8
TTP primarily affects young to middle-aged individuals, with a
median age at diagnosis of 40e55 years.1,9,10 Accordingly, the safety
and efﬁcacy of treatment of very old patients with TTP have not
been studied.
We report an 89-year-old man with TTP who presented with
cerebral infarction and was refractory to PEX despite the initial
response, and was subsequently treated successfully with ritux-
imab. To the best of our knowledge, this patient is the oldest re-
ported case of TTP successfully treated with rituximab, and shows
that PEX and rituximab can be applied safely to very elderly pa-
tients with TTP, and that advanced age should not be regarded, per
se, as a contraindication for such treatment.2. Case Presentation
An 89-year-old Japanese man presented with dysarthria and
recurrent episodes of paralysis of the left palm that started 1 week
earlier. He had no past medical history, except mild hypertension,lished by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
Figure 2. Clinical course after Day 40 in hospital. The hemoglobin level (Hb, di-
amonds), platelet count (Plt, squares), and lactate dehydrogenase level (LDH, triangles)
are graphically presented with treatments given. ADAMTS13 ¼ a disintegrin-like and
metalloprotease with thorombospondin type 1 motif 13; PEX ¼ plasma exchange.
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was not febrile and submucosal hemorrhage of the soft palate and
small subcutaneous hemorrhages on the chest and left upper ex-
tremity were noted. Neurological examination revealed that left
heelekneeeshin test was poor. The diffusion-weighted images of
magnetic resonance imaging revealed high-intensity signals in
bilateral cerebellar hemispheres, left frontal lobe, and left occipital
lobe (Figure 1) and he was diagnosed with acute or subacute
multiple cerebral infarction. The blood test revealed profound
thrombocytopenia and anemia and he was admitted to hospital.
The laboratory ﬁndings on admission were as follows: white
blood cell count 5.8  109/L with a normal differential, red blood
cell count 2.36  1012/L with 9% reticulocytes, hemoglobin 7.9 g/dL,
hematocrit 23.4%, and platelet count 1.2  1010/L. The examination
of the blood ﬁlm revealed fragmented red blood cells. The results of
coagulation studies were normal except for mildly elevated D-
dimer at 1.6 mg/mL. The blood chemistry showed creatinine
0.70 mg/dL, total bilirubin 3.4 mg/dL, direct bilirubin 0.9 mg/dL,
aspartate aminotransferase 45 U/L, alanine aminotransferase 18 U/
L, and lactate dehydrogenase (LDH) 844 U/L. Haptoglobin level was
below the level of detection. Both direct and indirect Coombs tests
were negative. Urinalysis revealed proteinuria and positive occult
blood but the sediments were unremarkable.
TTP was diagnosed on the basis of hemolytic anemia with
fragmented red blood cells and thrombocytopenia, and PEX was
immediately started with methylprednisolone at 0.5 mg/kg; a
reduced dose due to concern of his advance age. Several days later,
blood tests on admission revealed that ADAMTS13 activity was
<0.5%, inhibitor against ADAMTS13 was detected at 0.9 BU/mL, and
the diagnosis of acquired TTP was conﬁrmed.
The platelet count started to increase after two courses of PEX
and reached 1.5  1011/L after 12 courses of PEX over 16 days, with
normalization of LDH level. ADAMTS13 level also increased to 17.1%
and ADAMTS13 inhibitor became undetectable. PEX was graduallyFigure 1. MRI of the brain at presentation. The diffusion-weighted images of MRI revealed h
left occipital lobe compatible with acute or subacute multiple cerebral infarction (arrows).tapered to once weekly and stopped on Day 37 of hospitalization
after a total of 15 courses of PEX.
However, on Day 52 of hospitalization, 15 days after the last PEX,
the platelet count rapidly decreased with elevation of LDH level
(Figure 2). The ADAMTS13 activity again decreased to <0.5% with
reemergence of ADAMTS13 inhibitor at 0.6 BU/mL. Exacerbation of
TTP was diagnosed and daily PEX was resumed immediately. As the
TTP was judged to be refractory to PEX, rituximab 375 mg/m2 was
added weekly for 4 weeks, with the approval of the Institutional
Review Board, as rituximab is not approved for TTP in Japan. The
platelet count increased within 1 week and was maintainedigh-intensity signals in (A) bilateral cerebellar hemispheres and (B) left frontal lobe, and
MRI ¼ magnetic resonance imaging.
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activity was elevated again and ADAMTS13 inhibitor became unde-
tectable. He did not experience any adverse event associated with
rituximab, including infusion reaction. He is currently well without
any signs of relapse >1 year after the last rituximab dose and PEX.
3. Discussion
The introduction of PEX to the management of acquired TTP has
greatly improved the prognosis of patients whose mortality rate
was ~90% before the introduction of PEX.3 TTP patients who are
refractory to or relapse after PEX can be successfully treated with
rituximab, further improving the prognosis.3,7,8 However, as ac-
quired TTP primarily affects young to middle-aged adults, the ef-
ﬁciency and safety of these modalities for elderly patients are not
yet known.9,10 In fact, even though Japanese TTP patients are two
decades older than the other patients' cohort, the oldest patient at
onset of TTP among 186 Japanese patients was 87 years, and the
present case apparently belongs to the oldest age group of TTP
patients.9 Accordingly, our literature review revealed that large
studies of TTP patients treated with PEX included elderly patients
up to 87 years old.9,10 The present case demonstrates that TTP pa-
tients with even more advanced age can be safely treated with PEX
and also with rituximab.
To the best of our knowledge, the oldest TTP patient treatedwith
rituximab reported so far was 78 years old, and the safety and ef-
ﬁcacy of rituximab for TTP patients with very advanced age have
not been evaluated.6,7,11 The adverse events of rituximab, when
used to treat autoimmune hematological disorders such as auto-
immune thrombocytopenia12,13 or autoimmune hemolytic ane-
mia,14 are generally mild to moderate and well tolerated, however,
there is a possible risk of complicating severe infection.13,14 The
present case clearly indicates that very elderly patients with TTP
can be safely and successfully treated with rituximab and that the
management of such patients should be planned as for younger
patients.
Another characteristic of the present case was the uncommon
presentation of TTP, in that he presented with multiple cerebral
infarction. Transient focal neurological symptoms are common
symptoms of TTP,1 caused by platelet thrombi in terminal arterioles
and capillaries,2 however, cerebral infarction is not commonly
complicated with TTP.15,16 It is assumed that alterations in the
vascular system associated with aging contributed to the occlusion
of larger arteries and led to the uncommon presentation of TTP, and
that very old patients are apt to develop overt cerebral infarction
rather than transit ischemia, due to platelet microthrombi of ter-
minal arterioles.
In summary, rituximab was effective and safe in an 89-year-old
patient with refractory TTP and should be considered proactivelyfor patients with refractory TTP regardless of age. It is worth
keeping in mind that elderly patients with TTP may present with
cerebral infarction.Conﬂicts of interest
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